João Daniel Guedes

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial

Fred Saad, Noel W. Clarke, Mototsugu Oya et al. · The Lancet Oncology · 2023 · 288 citations · Full text

Medicine, Oncology, Pharmacology +16

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial

Christian Marth, Richard G. Moore, Mariusz Bidziński et al. · Journal of Clinical Oncology · 2024 · 58 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC).

Noel W. Clarke, Andrew J. Armstrong, Antoine Thiery-Vuillemin et al. · Journal of Clinical Oncology · 2023 · 53 citations

Medicine, Oncology, Pharmacology +16

Single-Agent Divarasib in Patients With <i>KRAS G12C</i> –Positive Non–Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study

Adrian G. Sacher, Wilson H. Miller, Manish R. Patel et al. · Journal of Clinical Oncology · 2025 · 21 citations · Full text

Medicine, Oncology, Pharmacology +16

Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial

Noel W. Clarke, Andrew J. Armstrong, Mototsugu Oya et al. · European Urology Oncology · 2024 · 17 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17